Literature DB >> 21271790

Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models.

Benjamin C Cheah1, Steve Vucic, Arun V Krishnan, Robert A Boland, Matthew C Kiernan.   

Abstract

Our objective was to evaluate the neurophysiological index (NI) as a biomarker for amyotrophic lateral sclerosis (ALS) and to assess the validity of linear mixed effects models for describing longitudinal changes. Functional assessment and nerve conduction studies were undertaken in 58 ALS patients. Neurophysiological data were collected on four occasions over 12 weeks (baseline, weeks 4, 8 and 12). The NI was calculated for the abductor digiti minimi and ulnar nerve at the wrist. NI declined at a rate of 0.04 per week (S.E. 0.006, p < 0.0001). Patients with bulbar-onset disease had 0.88 greater NI than patients with upper limb-onset disease over the follow-up period (S.E. 0.39, p = 0.03). There were no differences in the rates of decline among patients with different disease phenotypes. Rates of change in NI and functional impairment were weakly correlated (Spearman's p = 0.29, p = 0.03). Linear mixed effects models were appropriate for detailing the longitudinal changes in NI. The present findings support incorporation of NI as an outcome measure for ALS clinical trials conducted over short time periods.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21271790     DOI: 10.3109/17482968.2010.531742

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  15 in total

Review 1.  Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.

Authors:  Jeffrey Rosenfeld; Michael J Strong
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 2.  Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis.

Authors:  Seward B Rutkove
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

3.  Outcome measures in amyotrophic lateral sclerosis clinical trials.

Authors:  Sabrina Paganoni; Merit Cudkowicz; James D Berry
Journal:  Clin Investig (Lond)       Date:  2014

Review 4.  ALS biomarkers for therapy development: State of the field and future directions.

Authors:  Michael Benatar; Kevin Boylan; Andreas Jeromin; Seward B Rutkove; James Berry; Nazem Atassi; Lucie Bruijn
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

Review 5.  Controversies and priorities in amyotrophic lateral sclerosis.

Authors:  Martin R Turner; Orla Hardiman; Michael Benatar; Benjamin R Brooks; Adriano Chio; Mamede de Carvalho; Paul G Ince; Cindy Lin; Robert G Miller; Hiroshi Mitsumoto; Garth Nicholson; John Ravits; Pamela J Shaw; Michael Swash; Kevin Talbot; Bryan J Traynor; Leonard H Van den Berg; Jan H Veldink; Steve Vucic; Matthew C Kiernan
Journal:  Lancet Neurol       Date:  2013-03       Impact factor: 44.182

Review 6.  Antisense therapy in neurology.

Authors:  Joshua J A Lee; Toshifumi Yokota
Journal:  J Pers Med       Date:  2013-08-02

7.  Axonal Dysfunction Precedes Motor Neuronal Death in Amyotrophic Lateral Sclerosis.

Authors:  Yuta Iwai; Kazumoto Shibuya; Sonoko Misawa; Yukari Sekiguchi; Keisuke Watanabe; Hiroshi Amino; Satoshi Kuwabara
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240

Review 8.  Quantifying disease progression in amyotrophic lateral sclerosis.

Authors:  Neil G Simon; Martin R Turner; Steve Vucic; Ammar Al-Chalabi; Jeremy Shefner; Catherine Lomen-Hoerth; Matthew C Kiernan
Journal:  Ann Neurol       Date:  2014-09-30       Impact factor: 10.422

9.  Do We Have a Channel Solution for ALS?

Authors:  Mamede de Carvalho
Journal:  EBioMedicine       Date:  2015-12-03       Impact factor: 8.143

10.  Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.

Authors:  Susanna B Park; Steve Vucic; Benjamin C Cheah; Cindy S-Y Lin; Adrienne Kirby; Kristy P Mann; Margie C Zoing; Jennica Winhammar; Matthew C Kiernan
Journal:  EBioMedicine       Date:  2015-12-01       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.